



UNITED STATES PATENT AND TRADEMARK OFFICE

APR - 1 2008

Commissioner for Patents  
United States Patent and Trademark Office  
P.O. Box 1450  
Alexandria, VA 22313-1450  
www.uspto.gov

Office of Regulatory Policy  
Food and Drug Administration  
10903 New Hampshire Ave., Bldg. 51, Rm. 6222  
Silver Spring, MD 20993-0002

Attention: Beverly Friedman

Dear Ms. Axelrad:

Transmitted herewith is a copy of the application for patent term extension of U.S. Patent No. 6,639,055. The application was filed on August 23, 2004, under 35 U.S.C. § 156. Applicant also filed for patent term extension for U.S. Patent No. 6,054,297 for BLA No. 125085/0 (FDA Docket No. 2004E-0402).

The patent claims a product that was subject to regulatory review under the Federal Food, Drug and Cosmetic Act. Subject to final review, the subject patent is considered to be eligible for patent term extension. Thus, a determination by your office of the applicable regulatory review period is necessary. Accordingly, notice and a copy of the application are provided pursuant to 35 U.S.C. § 156(d)(2)(A).

Inquiries regarding this communication should be directed to the undersigned at (571)272-7755 (telephone) or (571) 273-7755 (facsimile).

Mary C. Till  
Legal Advisor  
Office of Patent Legal Administration  
Office of the Deputy Commissioner  
for Patent Examination Policy

cc: Jeffrey P. Kushan  
Sidley Austin Brown and Wood LLP  
1501 K Street NW  
Washington DC 20005

RE: AVASTIN® (bevacizumab)  
FDA Docket No. 2007E-0184